Fluorine 18 MNI 1020

Drug Profile

Fluorine 18 MNI 1020

Alternative Names: [18F]JNJ 64326067; [18F]MNI-1020

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Research & Development
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase 0 Alzheimer's disease

Most Recent Events

  • 13 Jul 2018 Janssen Research plans a phase-0 trial in Healthy volunteers in USA (NCT03581916)
  • 06 Sep 2017 Phase-0 for Alzheimer's disease (Diagnosis) in USA (IV) (NCT03239561)
  • 08 Aug 2017 Janssen Research & Development plans a phase 0 trial for Alzheimer's disease (Diagnosis) in USA in August 2017 (NCT03239561)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top